← Leaderboards
Metin Kurtoglu
Cartesian Therapeutics, Inc.
$1,990,216
Attributed
$1,990,216
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2020–21$2M$1.5M$1M$500K$0
'20
'21
Funding mix
By agency
NIH$1,990,216 · 1
By mechanism
R44$1,990,216 · 1
Top collaborators
No co-investigators on record.
Most similar at Cartesian Therapeutics, Inc.
Same institution · by research overlap
- Charles Andrew Stewart$5,769,845
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectAmericanAntigensAntigen TargetingAuthorityAutoantibodiesAutoimmune DiseasesAutologousBiological MarkersBloodB-LymphocytesBreathingCar T Cell TherapyCell MaturationCell TherapyChimeric Antigen ReceptorChimeric Antigen Receptor T CellsChronicClinical AssessmentsClinical RemissionClinical TrialsClone CellsCohortActivities Of Daily Living
Grant awards (2)
Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)$1,154,358
R44 · FY2021 · NS · contact PI
Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)$835,858
R44 · FY2020 · NS · contact PI